#USA #Fort Myers #Ultima Genomics #NeoGenomics #UG 100

Collaboration to Enhance Oncology Testing

In a significant move to advance clinical testing in oncology, NeoGenomics, Inc. and Ultima Genomics, Inc. have announced a partnership focused on utilizing Ultima's state-of-the-art UG 100™ sequencing platform. This collaboration marks a pivotal enhancement in the diagnostic capabilities of NeoGenomics, a leader in precision medicine for oncology diagnostics.

About the UG 100 Sequencing Platform

The UG 100 is designed with cutting-edge ppmSeq™ technology, which prioritizes cost-effective and high-fidelity sequencing while minimizing errors. The installation of this platform at NeoGenomics' innovation center in Cambridge, UK, will bolster their ability to offer a wide range of innovative clinical tests essential for cancer care. The UG 100's benefits extend beyond standard operations; it delivers a remarkable accuracy suitable for demanding applications, including liquid biopsies—crucial for detecting rare genetic mutations.

Innovations in Genetic Testing

Recent advancements such as the Solaris portfolio, introduced by Ultima, have amplified the sensitivity of variant detection, achieving five times the yield in the SNVQ60 ppmSeq™ mode. This technique enables next-generation sequencing coverage of 30X from a mere 2 nanograms of DNA, making it a revolutionary tool for locating crucial genetic biomarkers in complex samples.

As Tony Zook, CEO of NeoGenomics comments, “This collaboration with Ultima will arm our research and development teams with the essential tools to accelerate the innovation that benefits patient care.” The shared goal of enhancing patient outcomes through improved diagnostic techniques is central to their partnership and is expected to yield important breakthroughs in the field of oncology.

Strategic Significance in Oncology

The synergy between NeoGenomics and Ultima is underpinned by their complementary expertise. NeoGenomics is renowned for providing comprehensive cancer diagnostics, operating laboratories accredited by CAP and CLIA across the United States and a laboratory in the UK. This expansion empowers them to develop tests that address the full scope of cancer care, innovating across stages from early diagnosis through treatment monitoring and beyond.

Gilad Almogy, CEO of Ultima Genomics, shares his enthusiasm for the collaboration, saying, “We are thrilled to partner with NeoGenomics, as their solid presence in oncology diagnostics aligns perfectly with our aim to produce cost-efficient and scalable sequencing technologies.” Ultima Genomics is innovating to meet the rising demand for genomic information, crucial in an era where genomic insights are becoming central to personalized medicine.

Conclusion

As the landscape of oncology diagnostics continues to evolve, the collaboration between NeoGenomics and Ultima Genomics symbolizes an exciting future for cancer care. By leveraging advanced sequencing technologies like the UG 100, both companies aim to refine their testing offerings and enhance the precision of cancer diagnostics, ultimately striving for improved patient outcomes. This partnership not only addresses current needs in oncology but also stands at the forefront of the ongoing revolution in genomic medicine.